You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTiaprofenic acid
Accession NumberDB01600
TypeSmall Molecule
GroupsApproved
DescriptionTiaprofenic acid is a non-steroidal anti-inflammatory drug of the arylpropionic acid (profen) class, used to treat pain, especially arthritic pain.
Structure
Thumb
Synonyms
2-(5-Benzoyl-thiophen-2-yl)-propionic acid
2-(5-Benzyl-2-thienyl)propionsaeure
5-Benzoyl-alpha-methyl-2-thiopheneacetic acid
5-Benzoyl-alpha-methylthiophene-2-acetic acid
Acide tiaprofenique
Acido tiaprofenico
Acidum tiaprofenicum
alpha-Methyl-5-benzoyl-2-thienylacetic acid
Tiaprofensaeure
Tiaprofensäure
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Albert Tiafen SRcapsule (sustained-release)300 mgoralAventis Pharma IncNot applicableNot applicableCanada
Albert Tiafen Tab 200mgtablet200 mgoralAventis Pharma Inc1991-12-312004-07-30Canada
Albert Tiafen Tab 300mgtablet300 mgoralAventis Pharma Inc1991-12-312004-07-30Canada
Dom-tiaprofenictablet300 mgoralDominion Pharmacal2000-06-20Not applicableCanada
Dom-tiaprofenictablet200 mgoralDominion PharmacalNot applicableNot applicableCanada
Nu-tiaprofenic - Tab 200mgtablet200 mgoralNu Pharm Inc1995-12-312012-09-04Canada
Nu-tiaprofenic - Tab 300mgtablet300 mgoralNu Pharm Inc1995-12-312012-09-04Canada
Penta-tiaprofenic Tabletstablet300 mgoralPentapharm Ltd.Not applicableNot applicableCanada
Penta-tiaprofenic Tabletstablet200 mgoralPentapharm Ltd.Not applicableNot applicableCanada
PMS-tiaprofenictablet200 mgoralPharmascience Inc1999-01-24Not applicableCanada
PMS-tiaprofenictablet300 mgoralPharmascience Inc1997-07-08Not applicableCanada
Surgamtablet300 mgoralSanofi Aventis Canada Inc1997-08-202007-11-22Canada
Surgam SRcapsule (sustained-release)300 mgoralSanofi Aventis Canada Inc1997-02-212007-07-31Canada
Surgam SR Cap 300mgcapsule (sustained-release)300 mgoralHoechst Roussel Canada Inc.1990-12-311999-08-11Canada
Surgam Tab 200mgtablet200 mgoralRoussel Canada Inc.1986-12-311997-08-05Canada
Surgam Tab 200mgtablet200 mgoralHoechst Roussel Canada Inc.1996-12-312001-07-20Canada
Surgam Tab 300mgtablet300 mgoralHoechst Roussel Canada Inc.1995-12-311999-08-11Canada
Surgam Tab 300mgtablet300 mgoralRoussel Canada Inc.1986-12-311997-08-05Canada
Surgam-SR Src 300mgcapsule (sustained-release)300 mgoralRoussel Canada Inc.1990-12-311996-09-09Canada
Teva-tiaprofenic Acidtablet200 mgoralTeva Canada Limited1996-12-31Not applicableCanada
Teva-tiaprofenic Acidtablet300 mgoralTeva Canada Limited1996-12-31Not applicableCanada
Tiaprofenic-200 - Tabtablet200 mgoralPro Doc Limitee1996-12-312009-07-23Canada
Tiaprofenic-300 - Tabtablet300 mgoralPro Doc Limitee1996-12-312009-07-23Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-tiaprofenic Tablets -300mgtablet300 mgoralApotex Inc1994-12-31Not applicableCanada
Apo-tiaprofenic Tablets-200mgtablet200 mgoralApotex Inc1994-12-31Not applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
SurgamylNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII1LS1T6R34C
CAS number33005-95-7
WeightAverage: 260.308
Monoisotopic: 260.05071494
Chemical FormulaC14H12O3S
InChI KeyInChIKey=GUHPRPJDBZHYCJ-UHFFFAOYSA-N
InChI
InChI=1S/C14H12O3S/c1-9(14(16)17)11-7-8-12(18-11)13(15)10-5-3-2-4-6-10/h2-9H,1H3,(H,16,17)
IUPAC Name
2-(5-benzoylthiophen-2-yl)propanoic acid
SMILES
CC(C(O)=O)C1=CC=C(S1)C(=O)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as acetophenones. These are organic compounds containing the acetophenone structure.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassAcetophenones
Direct ParentAcetophenones
Alternative Parents
Substituents
  • Acetophenone
  • Aryl ketone
  • Thiophene carboxylic acid or derivatives
  • Benzoyl
  • 2,5-disubstituted thiophene
  • Heteroaromatic compound
  • Thiophene
  • Ketone
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationTiaprofenic acid is used to treat pain, especially arthritic pain.
PharmacodynamicsTiaprofenic acid is a non-steroidal anti-inflammatory drug of the arylpropionic acid (profen) class, used to treat pain, especially arthritic pain. The typical adult dose is 300mg twice daily. It is not recommended in children.
Mechanism of actionTiaprofenic acid belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). It works by blocking the production of a chemical (prostaglandin) which the body produces in response to injury or certain diseases. This prostaglandin would otherwise go on to cause swelling, pain and inflammation.
Related Articles
AbsorptionBioavailability is 90% following oral administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic (10%). Sparingly metabolised in the liver to two inactive metabolites.

Route of eliminationNot Available
Half life1.5-2.5 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Tiaprofenic Acid Action PathwayDrug actionSMP00705
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9927
Blood Brain Barrier+0.9289
Caco-2 permeable+0.6039
P-glycoprotein substrateNon-substrate0.7298
P-glycoprotein inhibitor INon-inhibitor0.9534
P-glycoprotein inhibitor IINon-inhibitor0.9664
Renal organic cation transporterNon-inhibitor0.8998
CYP450 2C9 substrateNon-substrate0.6293
CYP450 2D6 substrateNon-substrate0.9226
CYP450 3A4 substrateNon-substrate0.8098
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.8607
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.8958
CYP450 3A4 inhibitorNon-inhibitor0.9526
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.9398
CarcinogenicityNon-carcinogens0.7568
BiodegradationReady biodegradable0.7714
Rat acute toxicity3.1892 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9869
hERG inhibition (predictor II)Non-inhibitor0.9716
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral300 mg
Tabletoral200 mg
Capsule (sustained-release)oral300 mg
Prices
Unit descriptionCostUnit
Apo-Tiaprofenic 300 mg Tablet0.43USD tablet
Novo-Tiaprofenic 300 mg Tablet0.43USD tablet
Nu-Tiaprofenic 300 mg Tablet0.43USD tablet
Apo-Tiaprofenic 200 mg Tablet0.36USD tablet
Novo-Tiaprofenic 200 mg Tablet0.36USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point96 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.0324 mg/mLALOGPS
logP3.22ALOGPS
logP3.66ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)4.03ChemAxon
pKa (Strongest Basic)-7.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area54.37 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity69.19 m3·mol-1ChemAxon
Polarizability26.78 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesM01AE11
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabTiaprofenic acid may increase the anticoagulant activities of Abciximab.
AcebutololTiaprofenic acid may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Aceclofenac.
AcenocoumarolTiaprofenic acid may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Tiaprofenic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Tiaprofenic acid.
Alendronic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Alendronic acid.
AliskirenTiaprofenic acid may decrease the antihypertensive activities of Aliskiren.
AlprenololTiaprofenic acid may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Tiaprofenic acid.
AmikacinTiaprofenic acid may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideTiaprofenic acid may decrease the antihypertensive activities of Amiloride.
AncrodTiaprofenic acid may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Tiaprofenic acid.
Antithrombin III humanTiaprofenic acid may increase the anticoagulant activities of Antithrombin III human.
ApixabanTiaprofenic acid may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Apremilast.
ArdeparinTiaprofenic acid may increase the anticoagulant activities of Ardeparin.
ArgatrobanTiaprofenic acid may increase the anticoagulant activities of Argatroban.
ArotinololTiaprofenic acid may decrease the antihypertensive activities of Arotinolol.
AtenololTiaprofenic acid may decrease the antihypertensive activities of Atenolol.
AzapropazoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Tiaprofenic acid.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tiaprofenic acid.
BalsalazideTiaprofenic acid may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Tiaprofenic acid.
BecaplerminTiaprofenic acid may increase the anticoagulant activities of Becaplermin.
BefunololTiaprofenic acid may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Tiaprofenic acid.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tiaprofenic acid.
BenoxaprofenThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Benoxaprofen.
BetaxololTiaprofenic acid may decrease the antihypertensive activities of Betaxolol.
BevantololTiaprofenic acid may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Tiaprofenic acid.
BisoprololTiaprofenic acid may decrease the antihypertensive activities of Bisoprolol.
BivalirudinTiaprofenic acid may increase the anticoagulant activities of Bivalirudin.
BopindololTiaprofenic acid may decrease the antihypertensive activities of Bopindolol.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tiaprofenic acid.
BufuralolTiaprofenic acid may decrease the antihypertensive activities of Bufuralol.
BumetanideTiaprofenic acid may decrease the diuretic activities of Bumetanide.
BupranololTiaprofenic acid may decrease the antihypertensive activities of Bupranolol.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Tiaprofenic acid.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Tiaprofenic acid.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Tiaprofenic acid.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Tiaprofenic acid.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Tiaprofenic acid.
CarteololTiaprofenic acid may decrease the antihypertensive activities of Carteolol.
CarvedilolTiaprofenic acid may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Tiaprofenic acid.
CeliprololTiaprofenic acid may decrease the antihypertensive activities of Celiprolol.
CertoparinTiaprofenic acid may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Tiaprofenic acid.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tiaprofenic acid.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tiaprofenic acid.
CholestyramineCholestyramine can cause a decrease in the absorption of Tiaprofenic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tiaprofenic acid.
Citric AcidTiaprofenic acid may increase the anticoagulant activities of Citric Acid.
ClodronateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Tiaprofenic acid.
ColesevelamColesevelam can cause a decrease in the absorption of Tiaprofenic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Tiaprofenic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclosporineTiaprofenic acid may increase the nephrotoxic activities of Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with D-Limonene.
Dabigatran etexilateTiaprofenic acid may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinTiaprofenic acid may increase the anticoagulant activities of Dalteparin.
DanaparoidTiaprofenic acid may increase the anticoagulant activities of Danaparoid.
DaunorubicinTiaprofenic acid may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Deferasirox.
DesirudinTiaprofenic acid may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Tiaprofenic acid.
DextranTiaprofenic acid may increase the anticoagulant activities of Dextran.
Dextran 40Tiaprofenic acid may increase the anticoagulant activities of Dextran 40.
Dextran 70Tiaprofenic acid may increase the anticoagulant activities of Dextran 70.
Dextran 75Tiaprofenic acid may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Tiaprofenic acid.
DicoumarolTiaprofenic acid may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tiaprofenic acid.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Tiaprofenic acid.
DihydrostreptomycinTiaprofenic acid may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Tiaprofenic acid.
DoxorubicinTiaprofenic acid may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenoneTiaprofenic acid may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Droxicam.
Edetic AcidTiaprofenic acid may increase the anticoagulant activities of Edetic Acid.
EdoxabanTiaprofenic acid may increase the anticoagulant activities of Edoxaban.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Tiaprofenic acid.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Tiaprofenic acid.
EnoxaparinTiaprofenic acid may increase the anticoagulant activities of Enoxaparin.
EpirizoleThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Epirizole.
EpirubicinTiaprofenic acid may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneTiaprofenic acid may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tiaprofenic acid.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tiaprofenic acid.
EsmololTiaprofenic acid may decrease the antihypertensive activities of Esmolol.
Etacrynic acidTiaprofenic acid may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Tiaprofenic acid.
Ethyl biscoumacetateTiaprofenic acid may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Tiaprofenic acid.
EtofenamateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Etoricoxib.
Evening primrose oilThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with exisulind.
FenbufenThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Tiaprofenic acid.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Tiaprofenic acid.
FlunixinThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Tiaprofenic acid.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Tiaprofenic acid.
Fondaparinux sodiumTiaprofenic acid may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Tiaprofenic acid.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Tiaprofenic acid.
FramycetinTiaprofenic acid may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideTiaprofenic acid may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Tiaprofenic acid.
GentamicinTiaprofenic acid may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Haloperidol.
HeparinTiaprofenic acid may increase the anticoagulant activities of Heparin.
HirulogTiaprofenic acid may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with HMPL-004.
HydralazineTiaprofenic acid may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tiaprofenic acid.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tiaprofenic acid.
Hygromycin BTiaprofenic acid may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Tiaprofenic acid.
IbuproxamThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Icatibant.
IdarubicinTiaprofenic acid may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tiaprofenic acid.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tiaprofenic acid.
IndenololTiaprofenic acid may decrease the antihypertensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tiaprofenic acid.
IndoprofenThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tiaprofenic acid.
IsoxicamThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Isoxicam.
KanamycinTiaprofenic acid may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Tiaprofenic acid.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Tiaprofenic acid.
LabetalolTiaprofenic acid may decrease the antihypertensive activities of Labetalol.
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Tiaprofenic acid.
LepirudinTiaprofenic acid may increase the anticoagulant activities of Lepirudin.
LevobunololTiaprofenic acid may decrease the antihypertensive activities of Levobunolol.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Tiaprofenic acid.
LithiumThe serum concentration of Lithium can be increased when it is combined with Tiaprofenic acid.
LornoxicamThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Tiaprofenic acid.
LoxoprofenThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Tiaprofenic acid.
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Tiaprofenic acid.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tiaprofenic acid.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tiaprofenic acid.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tiaprofenic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Tiaprofenic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tiaprofenic acid.
MesalazineTiaprofenic acid may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Tiaprofenic acid.
MetamizoleThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Metamizole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Tiaprofenic acid.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tiaprofenic acid.
MetipranololTiaprofenic acid may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tiaprofenic acid.
MetoprololTiaprofenic acid may decrease the antihypertensive activities of Metoprolol.
MetrizamideTiaprofenic acid may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Tiaprofenic acid.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Tiaprofenic acid.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Tiaprofenic acid.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tiaprofenic acid.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tiaprofenic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Tiaprofenic acid.
NadololTiaprofenic acid may decrease the antihypertensive activities of Nadolol.
NadroparinTiaprofenic acid may increase the anticoagulant activities of Nadroparin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Tiaprofenic acid.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Tiaprofenic acid.
NCX 4016The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with NCX 4016.
NeomycinTiaprofenic acid may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Nepafenac.
NetilmicinTiaprofenic acid may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
Niflumic AcidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Niflumic Acid.
NimesulideThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Nimesulide.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tiaprofenic acid.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tiaprofenic acid.
OlsalazineTiaprofenic acid may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Tiaprofenic acid.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Tiaprofenic acid.
OrgoteinThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Orgotein.
OtamixabanTiaprofenic acid may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tiaprofenic acid.
OxprenololTiaprofenic acid may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Oxyphenbutazone.
PamidronateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Pamidronate.
ParecoxibThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Parecoxib.
ParomomycinTiaprofenic acid may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololTiaprofenic acid may decrease the antihypertensive activities of Penbutolol.
Pentosan PolysulfateTiaprofenic acid may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Tiaprofenic acid.
PhenindioneTiaprofenic acid may increase the anticoagulant activities of Phenindione.
PhenprocoumonTiaprofenic acid may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Tiaprofenic acid.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tiaprofenic acid.
PindololTiaprofenic acid may decrease the antihypertensive activities of Pindolol.
PiretanideTiaprofenic acid may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tiaprofenic acid.
PlicamycinTiaprofenic acid may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Tiaprofenic acid.
PorfimerTiaprofenic acid may increase the photosensitizing activities of Porfimer.
PractololTiaprofenic acid may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Tiaprofenic acid.
ProbenecidThe serum concentration of Tiaprofenic acid can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Propacetamol.
PropranololTiaprofenic acid may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Tiaprofenic acid.
Protein CTiaprofenic acid may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeTiaprofenic acid may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with PTC299.
PuromycinTiaprofenic acid may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Tiaprofenic acid.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tiaprofenic acid.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Tiaprofenic acid.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tiaprofenic acid.
ResveratrolThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Resveratrol.
ReviparinTiaprofenic acid may increase the anticoagulant activities of Reviparin.
RibostamycinTiaprofenic acid may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RisedronateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Risedronate.
RivaroxabanTiaprofenic acid may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Tiaprofenic acid.
SalicylamideThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Tiaprofenic acid.
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Tiaprofenic acid.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tiaprofenic acid.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Tiaprofenic acid.
SeratrodastThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Seratrodast.
SotalolTiaprofenic acid may decrease the antihypertensive activities of Sotalol.
SpectinomycinTiaprofenic acid may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Tiaprofenic acid.
SpironolactoneTiaprofenic acid may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with SRT501.
StreptomycinTiaprofenic acid may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinTiaprofenic acid may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfasalazineTiaprofenic acid may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tiaprofenic acid.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Tiaprofenic acid.
SulodexideTiaprofenic acid may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Tiaprofenic acid.
TacrolimusTiaprofenic acid may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Tiaprofenic acid.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Tiaprofenic acid.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tiaprofenic acid.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Tiaprofenic acid.
TenofovirThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Tiaprofenic acid.
TepoxalinThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Teriflunomide.
TiludronateThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Tiludronate.
TimololTiaprofenic acid may decrease the antihypertensive activities of Timolol.
TobramycinTiaprofenic acid may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tiaprofenic acid.
TorasemideTiaprofenic acid may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Tiaprofenic acid.
TranilastThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Tranilast.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tiaprofenic acid.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tiaprofenic acid.
TriamtereneTiaprofenic acid may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tiaprofenic acid.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Tiaprofenic acid.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Tiaprofenic acid.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Tiaprofenic acid.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Tiaprofenic acid.
VerteporfinTiaprofenic acid may increase the photosensitizing activities of Verteporfin.
WarfarinTiaprofenic acid may increase the anticoagulant activities of Warfarin.
XimelagatranTiaprofenic acid may increase the anticoagulant activities of Ximelagatran.
ZaltoprofenThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Tiaprofenic acid.
Zoledronic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Zomepirac.
Food Interactions
  • Avoid alcohol.
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Brandt KD, Albrecht ME, Kalasinski LA: Effects of tiaprofenic acid on the concentration and metabolism of proteoglycans in normal and degenerating canine articular cartilage. J Clin Pharmacol. 1990 Sep;30(9):808-14. [PubMed:2277128 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Patrignani P: Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. Thromb Res. 2003 Jun 15;110(5-6):281-6. [PubMed:14592549 ]
  2. Gupta K, Kaub CJ, Carey KN, Casillas EG, Selinsky BS, Loll PJ: Manipulation of kinetic profiles in 2-aryl propionic acid cyclooxygenase inhibitors. Bioorg Med Chem Lett. 2004 Feb 9;14(3):667-71. [PubMed:14741265 ]
  3. Martic M, Tatic I, Markovic S, Kujundzic N, Kostrun S: Synthesis, biological activity and molecular modeling studies of novel COX-1 inhibitors. Eur J Med Chem. 2004 Feb;39(2):141-51. [PubMed:14987823 ]
  4. Hillarp A: [Acetylsalicylic acid resistance--clinical diagnosis with unclear mechanism]. Lakartidningen. 2004 Nov 4;101(45):3504-6, 3508-9. [PubMed:15575422 ]
Comments
comments powered by Disqus
Drug created on August 29, 2007 12:44 / Updated on August 17, 2016 12:23